Why Traditional Valuation Fails in the Life Sciences Valuation in the life sciences deviates fundamentally from the rules governing software […]
The Math of Medicine: A Professional Guide to Biopharma Valuation Read Post »
The Disconnect Between Science and Spreadsheet Valuing a biotechnology or pharmaceutical company differs from evaluating a standard cash-flow-positive business. In
How to Value a Life-Saving Drug Without Overpaying Read Post »
The geographic distribution of pharmaceutical patent litigation in the United States is currently undergoing its most significant realignment since the
Executive Strategic Analysis The pharmaceutical sector currently faces a structural conflict between two divergent regulatory and legal regimes: the intellectual
Patent Infringement Liabilities and Regulatory Arbitrage in Pharmacy Compounding Read Post »
The End of the Binary Patent System The pharmaceutical industry has historically operated under a binary commercial model: a drug
The Playbook of Serial Patent Enforcement in Brand-Name Drug Defense Read Post »
The pharmaceutical industry operates on a foundation unlike any other. At its core, it is a high-stakes, capital-intensive ecosystem built
Developing a Global Drug Patent Strategy: From Legal Documents to Competitive Advantage Read Post »
The Unavoidable Collision: Compounding, Patents, and the Pursuit of Public Health A Strategic Crossroads The pharmaceutical landscape is a complex
Compounding vs. Patents: Can Innovation and Regulation Coexist? Read Post »
1. Executive Summary: The Structural Transformation of Exclusivity The pharmaceutical sector operates on a fundamental economic premise: the patent bargain.
Executive Summary: The New Intelligence Paradigm The global pharmaceutical sector is currently navigating a period of structural volatility that is
Get fresh news and insights, drug patent expirations & more…
